Abbelight provides a super-resolution microscopy platform that integrates sample preparation, imaging, and data analysis to deliver reproducible quality data for biological research. Their technology enables high-throughput imaging and comprehensive data visualization, facilitating insights into cellular structures and processes.

AlidaBio provides the EpiPlex platform, a proximity‑barcoding workflow that simultaneously detects m6A, inosine, and pseudouridine alongside whole‑transcriptome expression from low‑input or degraded RNA samples such as FFPE and liquid biopsies. The solution is offered as a turnkey service or in‑lab kits, with machine‑learning‑driven EpiScout software delivering normalized quantification, quality metrics, and visual reports in a single, seven‑hour workflow.

Basilard BioTech develops Celletto™, a novel nanomechanical gene delivery platform for Cell and Gene Therapy (CGT) engineering. This mechanoporation solution delivers genes to the cell nucleus efficiently without compromising viability. Celletto™ addresses manufacturing bottlenecks by offering a more scalable and cost-effective alternative to traditional viral and non-viral gene delivery methods.

Clearcut Surgical develops an integrated surgical device combining electrosurgery, continuous smoke evacuation, and on-demand fluid suction. This all-in-one tool is designed to enhance efficiency and safety for surgical teams during procedures. The device aims to improve overall operative outcomes by streamlining essential functions into a single platform.

Constructive.Bio utilizes a dual-technology platform that combines de novo genome synthesis and engineered translation to create programmable biomolecules with high fidelity. This approach addresses the limitations of traditional biomanufacturing by enabling the production of customized bioproducts, including phage-resistant strains and next-generation therapeutics.

This startup provides cryogenic electron microscopy (cryo-EM) services, including sample preparation, data acquisition, and image processing, to enable scientists to study biological molecules at the atomic level. They prepare diverse biological samples like proteins, viruses, and cells for cryo-EM analysis.

Eleni Health provides the Pareli Relief Patch, a wearable device that combines heat and TENS therapy to manage menstrual pain. The patch utilizes real-time physiological sensors to guide personalized, optimized treatment settings. A companion digital health app allows users to track symptoms, manage settings, and receive guidance from a virtual therapist.

nExodigm develops extracellular sensors that monitor intracellular genomic and transcriptomic content in living cells. This technology enables researchers to select, track, and study specific cells based on their genomic content for various research applications. By providing real-time genomic information, nExodigm ensures researchers work with the precise cells they need.

Partillion Bioscience has developed a nanovial platform that enables the rapid compartmentalization and analysis of millions of single cells to investigate biological functions, such as secreted proteins. This technology addresses the challenge of high costs and inefficiencies in traditional single-cell assays, allowing researchers to screen up to one million cells per experiment without the need for new equipment.

The startup develops biodegradable superabsorbent polymers that absorb and retain significant amounts of fluids while decomposing naturally. These microplastic-free polymers provide a sustainable alternative for various industries, enabling the creation of environmentally friendly products without compromising performance.

scellgen develops innovative solutions for comprehensive, multiplexed analysis of chromatin modifications and gene expression. The company focuses on enabling new insights within the field of epigenomics. Their technology operates specifically at the single-cell level for detailed molecular profiling.

Surf Therapeutics develops a patented broad beam ultrasound platform designed to safely activate the body's cholinergic anti-inflammatory pathway. This non-invasive stimulation prompts the release of natural neurotransmitters to restore immune balance, shifting the body away from uncontrolled inflammation. The technology aims to provide therapeutic benefits and potentially long-lasting relief for inflammatory disorders without reliance on pharmaceuticals.

Switchback Systems has developed a scalable benchtop DNA synthesis platform that integrates oligonucleotide synthesis and gene assembly capabilities, significantly reducing the time, cost, and waste associated with traditional DNA synthesis methods. This technology empowers scientists across various industries, including pharmaceuticals and agriculture, to efficiently produce custom DNA sequences for research and development.

This biotechnology company provides adaptive and scalable simulations of human physiology to accelerate drug discovery. Their platform helps research institutes improve the efficiency of drug development by offering accurate insights into drug performance.

This biotechnology company specializes in the field of Targeted Protein Degradation (TPD). They develop novel therapeutic modalities aimed at selectively eliminating disease-causing proteins within cells. Their focus is on advancing small molecule approaches to modulate protein homeostasis for therapeutic benefit.

Tavira Therapeutics is developing a modular AAV capsid platform to enhance tissue-specific transgene delivery for gene therapy applications. This technology aims to improve the precision and efficacy of gene therapies by targeting specific tissues, thereby increasing therapeutic outcomes.

Trench Therapeutics develops live biotherapeutic products derived from the human nasal microbiome to prevent and treat infectious and inflammatory diseases of the upper airway.

Wespran uses biomimetic enzymatic electrocatalysis on carbon‑nanotube electrodes to capture CO₂ from industrial streams and convert it into methanol and other chemicals at ambient temperature and pressure, using only water and electricity. The system operates on‑site for CO₂ concentrations from 1% to 100%, eliminating hydrogen requirements and reducing transport‑related emissions while generating marketable products.